Ondine Biomedical Inc. announced an operational update on its LANTERN Phase 3 pivotal study. The study, evaluating the Company's non-antibiotic nasal photodisinfection technology (branded as Steriwave® outside the US) remains on schedule to report top-line results in Spring 2026 in line with prior guidance. With 93% of patients enrolled across 14 HCA Healthcare hospitals and four major Canadian centres, the LANTERN study is entering its final stages of recruitment, data collection and verification, and continues to meet projected data quality and monitoring benchmarks: · Data integrity:Over 92% of clinical report forms are complete with 92% of all database queries successfully resolved.
Monitoring progress:80% of monitoring visits are now complete. Endpoint adjudication:Nearly 80% of all primary endpoint adjudications are complete. Participant retention:Follow-up completion currently exceeds 98%.
Topline analysis will commence immediately following completion of endpoint adjudication and database lock. Reporting will include the estimated treatment effect of surgical site infection rate reduction (derived from a generalized linear mixed-effects model comparing treatment to control arm), as well as primary safety data.
